Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

ProRx LLC

Has ProRx LLC received an FDA warning letter? Yes. FDA issued a warning letter dated April 7, 2026 concerning products containing tirzepatide and semaglutide.

Letter facts

Letter date
April 7, 2026 (2026-04-07)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Compounding Pharmacy
Products named
Tirzepatide Injection 27mg/3mLTirzepatide Injection 45mg/2.5mLTirzepatide 72MG/4ML injectableTirzepatide 45MG/2.5ML injectableSemaglutide InjectionNicotinamide Adenine Dinucleotide Injection 1200mgGlutathione Injection 2000mg
Violation categories
Unapproved new drugMisbrandingCompounding outside 503A/503BCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Compounding outside 503A/503B

FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says the firm compounded tirzepatide using a bulk drug substance not on the 503B bulks list or the drug shortage list, and cited missing label statements, inadequate adverse event reporting, insanitary aseptic practices, CGMP violations, and unapproved and misbranded drugs. The letter notes the firm recalled tirzepatide and semaglutide lots for sterility assurance.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Failure to meet section 503B conditions
  • Adulterated drug products - insanitary conditions (501(a)(2)(A))
  • Adulterated drug products - CGMP violations (501(a)(2)(B))
  • Unapproved new drug products
  • Misbranded drug products - inadequate directions for use (502(f)(1))

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.